CN102532834A - In-vivo degradable polymer tubular material for subcutaneous implantation of capsules and preparation method thereof - Google Patents
In-vivo degradable polymer tubular material for subcutaneous implantation of capsules and preparation method thereof Download PDFInfo
- Publication number
- CN102532834A CN102532834A CN2011104355023A CN201110435502A CN102532834A CN 102532834 A CN102532834 A CN 102532834A CN 2011104355023 A CN2011104355023 A CN 2011104355023A CN 201110435502 A CN201110435502 A CN 201110435502A CN 102532834 A CN102532834 A CN 102532834A
- Authority
- CN
- China
- Prior art keywords
- polymer
- tubulose
- capsular
- vivo degradation
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an in-vivo degradable polymer tubular material for subcutaneous implantation of capsules and a preparation method of the material. The preparation method comprises the steps of: (1) uniformly dispersing degradable polymer blend in organic solvent to form a polymer solution, stirring to be uniform, standing and debubbling; (2) forming polymer tubular film on a cylindrical mold surface from the polymer solution obtained in the step (1) by a pulling method, drying at room temperature for 1h to finish one pulling and molding cycle, repeating the pulling and molding cycle to achieve an expected thickness, and finally vacuum-drying at 40 DEG C for 24h to remove organic solvent and obtain a product; and (3) immersing the product obtained in the step (2) in deionized water for 3h, taking out, soaking in a solution formed from deionized water and absolute ethanol at a volume ratio of 1:1 for 1h, taking out, drying, then immersing in deionized water for 3h, and demolding to obtain the polymer tubular material. According to the invention, the used material is the degradable polymer with excellent biological compatibility; the inside diameter of the obtained tubular material is determined by the diameter of the cylindrical mold; and the obtained tubular material is suitable for subcutaneous implantation of controlled release substances.
Description
Technical field
What the present invention relates to is a kind of bio-medical material, but is used for the capsular vivo degradation polymer of subdermal implantation tubulose material specifically.
Background technology
Along with the continuous development of Materials science and medical science, in the Application Areas of bio-medical material, nondegradable macromolecular material is little by little replaced by degradable high polymer material.After nondegradable macromolecular material implants, can for good and all exist, the reaction that causes inflammation exists bad hidden danger.So people are constantly studying, developing degradable high polymer material, make them can reduce the detrimentally affect of body so to greatest extent along with the regeneration of organ or tissue is little by little degraded, absorbed and excretes.Because Biodegradable material decomposes easily in vivo, its degradation production can metabolism, and finally excretes, thereby more and more receives people's attention.
Polylactic acid-glycolic guanidine-acetic acid multipolymer (poly (lactic-co-glycolic acid); PLGA) by two kinds of monomers---lactic acid and oxyacetic acid are polymerized at random; It is a kind of degradable functional polymer organic cpds; Have excellent biological compatibility, nontoxic, good encystation and film forming performance, be widely used in pharmacy, medical engineering material and modernized industrial field.
(with molecular weight 20000 is benchmark for PEG or PEO (poly (ethylene oxide)); Molecular weight is higher than 20000 the PEO that is commonly referred to, and is lower than 20000 the PEG that is called), chemical molecular formula is (CH2CH2O-) n; Form by ethylene oxide polymerization; Be a kind of nontoxicity, nonirritant, have good water-solubility, and the crystal polymer thing of good intermiscibility is arranged with many organic constituentses; In industries such as makeup, pharmacy, chemical fibre, rubber, plastics, papermaking, paint, plating, agricultural chemicals, metal processing and food-processing, all have and use very widely, be the good polymer materials of biocompatibility of human implantable by drugs approved by FDA at present.
Publication number is to disclose a kind of small-bore thin-walled degradable tubular macromolecular material and low-pressure injection molding preparation method thereof in the patent document of CN 1487025 A; The gained tubular material is applicable to fields such as blood vessel, neural reparation; The generation of toxic side effect such as can avoiding or diminish inflammation after implanting is to meet biomedical requirement better.Publication number is to disclose in PLGA matrix in the patent document of CN 101522169 A to disperse hydrophilic excipient, has obtained to have changed overall lasting time of releasing at the subcutaneous implant that prolongs the following period of time release of active ingredients.
Yet; Serve as the capsular superpolymer tubular material of subdermal implantation; Be that disclosed pharmaceutical carrier is nondegradable medical grade silicon rubber in the patent document of CN 2712349 Y and CN201150664 Y like publication number, after drug release finished, the second operation of still needing took out; When increasing the operation cost, also cause once more grieved to the patient.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical carrier coupling relative medicine that can be used as; Realize that specific drug effect discharges; Carrier can be accomplished vivo degradation simultaneously; Human body is not produced detrimentally affect, but effectively avoid injury that second operation brings be used for the capsular vivo degradation polymer of subdermal implantation tubulose material.But the present invention also aims to provide a kind of capsular vivo degradation polymer of subdermal implantation tubulose preparation methods that is used for.
The objective of the invention is to realize like this:
But the capsular vivo degradation polymer of the subdermal implantation tubulose material that is used for of the present invention is the degradable polymer blend that is obtained by the PLGA of L type or DL type and PEG or the PEO mode through physical blending; The polymer tubulose material that uses crystal pulling method to process, wherein the shared mass ratio of PEG or PEO is 1～40%.
The molecular weight of the PLGA of said L type or DL type is 10000～200000.
The molecular weight of said PEG or PEO is 4000～800000.
But the capsular vivo degradation polymer of the subdermal implantation tubulose preparation methods that is used for of the present invention is:
(1) the degradable polymer blend is evenly spread in the organic solvent, form macromolecular solution, be stirred to evenly and standing and defoaming;
(2) in step (1) gained macromolecular solution, use crystal pulling method; Make the columnar mould surface form the polymer periosteum, drying at room temperature 1h accomplishes one and lifts the moulding circulation, lifts the moulding circulation repeatedly; Reach expection thickness, final 40 ℃ of vacuum-drying 24h Ex-all organic solvents get goods;
(3) step (2) resulting product immerses deionized water and soaks 3h, and the solution that took out the volume ratio of putting into by deionized water and absolute ethyl alcohol and be 1: 1 soaks 1h, takes out dryly, immerses deionized water immersion 3h once more, and the demoulding obtains polymer tubulose material.
Preparing method of the present invention can also comprise:
1. the polymkeric substance of said degradability is the PLGA blend; Be to be the blend that PLGA and the molecular weight of 10000～200000 L type or DL type obtains in 4000～800000 PEG or the PEO mode through physical blending by molecular weight, wherein the shared mass ratio of PEG or PEO is 1～40%.
2. the length 10～65mm of said polymer tubulose material, internal diameter 1～6mm, thickness of pipe 0.01～1mm.
The present invention is to be origin with the biodegradable polymer P LGA that ratified by U.S. FDA; Through adding a certain proportion of PEG or PEO, obtain PLGA blend tubular body, to improve the plasticity of PLGA itself; And regulate the drug release behavior of PLGA through the interpolation of blend phase; Be used for the subdermal implantation capsule, realize that specific drug effect discharges, and can effectively overcome above-mentioned defective simultaneously.
The present invention has following advantage:
1. but a kind of capsular vivo degradation polymer of subdermal implantation tubulose material that is used for provided by the invention has better biocompatibility and good degradability, the inflammatory reaction that causes when exempting subdermal implantation; Simultaneously; Can progressively degrade with the heeling-in time, end product is carbonic acid gas and water, excretes with metabolism; To human body toxicological harmless effect, avoided second operation to take out the pain of injury that implant brings to the patient;
2. but one kind is used for the capsular vivo degradation polymer of subdermal implantation tubulose material, and this high polymer material mechanical property is better, and film forming properties is preferable, has excellent processability.
Adopting the polymer blending legal system to be equipped with novel composite material is a kind of valid approach, can obtain two kinds of premium propertiess that material is had separately.Improve self elastoplasticity of PLGA through adding the good softening agent of biocompatibility, can obtain that comixing compatibility is good, the obvious enhanced PLGA of elastoplasticity blend film.The blend that the polymer tubulose material that the present invention selects is to use PLGA and PEG or the PEO mode through physical blending to obtain, two blend group element ratios are that PEG or PEO:PLGA are 1～40%.This intermingling material finally becomes small molecules through degraded in vivo, by human body institute's metabolism with excrete, avoided because current subcutaneous implant tubular carrier non-degradable, discharge the drawback that finishes and still need and perform the operation once more in specific drug effect.
The carrier degradation behavior is regulated in the interpolation of the present invention through the blend phase, thereby obtains the solid support material of specific degradation cycle, but and finally is prepared into a kind of vivo degradation polymer tubulose material that can be used for subcutaneous implant carrier.
Description of drawings
Fig. 1 is the tubular material surface SEM photo of PLGA/10%PEG for the blend constituent element.
Fig. 2 is the external degradation quality change curve of different ratios PLGA/PEG blend constituent element tubular material.
Embodiment
Provide embodiments of the invention below the present invention is further specified, rather than limit scope of the present invention.
Embodiment one: 0.90g PLGA (PL: GA 85/15 Mw:65000) and 0.10g PEG (Mw:6000) are dissolved in the 10ml methylene dichloride, stir and form uniform macromolecular solution, and standing and defoaming, subsequent use; In the gained uniform solution, adopt crystal pulling method, make the columnar mould surface form the polymer periosteum, drying at room temperature 1h lifts moulding once more, and 5 times repeatedly, but reaching phase thickness, final 40 ℃ of vacuum-drying 24h are with the Ex-all organic solvent; Resulting product immerses deionized water and soaks 24h, and the demoulding obtains polymer tubulose goods, internal diameter 3mm, and the about 0.02mm of wall thickness, gained tubular material surface topography is as shown in Figure 1, and external degradation quality change curve is shown in Fig. 2-A.
Embodiment two: 0.95g PLGA (PL: GA 85/15 Mw:65000) and 0.05g PEG (Mw:6000) are dissolved in the 10ml methylene dichloride, stir and form uniform macromolecular solution, and standing and defoaming, subsequent use; In the gained uniform solution, adopt crystal pulling method, make the columnar mould surface form the polymer periosteum, drying at room temperature 1h lifts moulding once more, and 5 times repeatedly, but reaching phase thickness, final 40 ℃ of vacuum-drying 24h are with the Ex-all organic solvent; Resulting product immerses deionized water and soaks 24h, and the demoulding obtains polymer tubulose goods, internal diameter 3mm, and the about 0.02mm of wall thickness, gained tubular material external degradation quality change curve is shown in Fig. 2-B.
Embodiment three: 0.90g PLGA (PL: GA 75/25 Mw:100000) and 0.10g PEG (Mw:6000) are dissolved in the 10ml methylene dichloride, stir and form uniform macromolecular solution, and standing and defoaming, subsequent use; In the gained uniform solution, adopt crystal pulling method, make the columnar mould surface form the polymer periosteum, drying at room temperature 1h lifts moulding once more, and 5 times repeatedly, but reaching phase thickness, final 40 ℃ of vacuum-drying 24h are with the Ex-all organic solvent; Resulting product immerses deionized water and soaks 24h, and the demoulding obtains polymer tubulose goods, internal diameter 3mm, and the about 0.02mm of wall thickness, gained tubular material external degradation quality change curve is shown in Fig. 2-C curve.
Embodiment four: 0.95g PLGA (PL: GA 75/25 Mw:100000) and 0.05g PEG (Mw:6000) are dissolved in the 10ml methylene dichloride, stir and form uniform macromolecular solution, and standing and defoaming, subsequent use; In the gained uniform solution, adopt crystal pulling method, make the columnar mould surface form the polymer periosteum, drying at room temperature 1h lifts moulding once more, and 5 times repeatedly, but reaching phase thickness, final 40 ℃ of vacuum-drying 24h are with the Ex-all organic solvent; Resulting product immerses deionized water and soaks 24h, and the demoulding obtains polymer tubulose goods, internal diameter 3mm, and the about 0.02mm of wall thickness, gained tubular material external degradation quality change curve is shown in Fig. 2-D.
Claims (8)
1. but one kind is used for the capsular vivo degradation polymer of subdermal implantation tubulose material; It is characterized in that: be the degradable polymer blend that obtains by the PLGA of L type or DL type and PEG or the PEO mode through physical blending; The polymer tubulose material that uses crystal pulling method to process, wherein the shared mass ratio of PEG or PEO is 1～40%.
2. but the capsular vivo degradation polymer of the subdermal implantation tubulose material that is used for according to claim 1, it is characterized in that: the molecular weight of the PLGA of said L type or DL type is 10000～200000.
3. but the capsular vivo degradation polymer of the subdermal implantation tubulose material that is used for according to claim 1 and 2, it is characterized in that: the molecular weight of said PEG or PEO is 4000～800000.
4. but the capsular vivo degradation polymer of the subdermal implantation tubulose material that is used for according to claim 1 and 2 is characterized in that: the length 10～65mm of said polymer tubulose material, internal diameter 1～6mm, thickness of pipe 0.01～1mm.
5. but the capsular vivo degradation polymer of the subdermal implantation tubulose material that is used for according to claim 3 is characterized in that: the length 10～65mm of said polymer tubulose material, internal diameter 1～6mm, thickness of pipe 0.01～1mm.
6. but one kind is used for the capsular vivo degradation polymer of subdermal implantation tubulose preparation methods, it is characterized in that comprising the steps:
(1) the degradable polymer blend is evenly spread in the organic solvent, form macromolecular solution, be stirred to evenly and standing and defoaming;
(2) in step (1) gained macromolecular solution, use crystal pulling method; Make the columnar mould surface form the polymer periosteum, drying at room temperature 1h accomplishes one and lifts the moulding circulation, lifts the moulding circulation repeatedly; Reach expection thickness, final 40 ℃ of vacuum-drying 24h Ex-all organic solvents get goods;
(3) step (2) resulting product immerses deionized water and soaks 3h, and the solution that took out the volume ratio of putting into by deionized water and absolute ethyl alcohol and be 1: 1 soaks 1h, takes out dryly, immerses deionized water immersion 3h once more, and the demoulding obtains polymer tubulose material.
7. but the capsular vivo degradation polymer of the subdermal implantation tubulose preparation methods that is used for according to claim 6; It is characterized in that: the polymkeric substance of said degradability is the PLGA blend; Be to be the blend that PLGA and the molecular weight of 10000～200000 L type or DL type obtains in 4000～800000 PEG or the PEO mode through physical blending by molecular weight, wherein the shared mass ratio of PEG or PEO is 1～40%.
8. but according to claim 6 or the 7 described capsular vivo degradation polymer of the subdermal implantation tubulose preparation methods that are used for, it is characterized in that: the length 10～65mm of said polymer tubulose material, internal diameter 1～6mm, thickness of pipe 0.01～1mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110435502 CN102532834B (en) | 2011-12-22 | 2011-12-22 | In-vivo degradable polymer tubular material for subcutaneous implantation of capsules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110435502 CN102532834B (en) | 2011-12-22 | 2011-12-22 | In-vivo degradable polymer tubular material for subcutaneous implantation of capsules and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102532834A true CN102532834A (en) | 2012-07-04 |
| CN102532834B CN102532834B (en) | 2013-07-03 |
Family
ID=46340942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110435502 Active CN102532834B (en) | 2011-12-22 | 2011-12-22 | In-vivo degradable polymer tubular material for subcutaneous implantation of capsules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102532834B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111467581A (en) * | 2020-04-14 | 2020-07-31 | 广东赛珐生物科技有限公司 | Glaucoma drainage tube and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1487025A (en) * | 2003-07-30 | 2004-04-07 | 复旦大学 | Thin-wall degradable tubular polymer material and its melting and injection molding process |
| CN1569253A (en) * | 2004-04-23 | 2005-01-26 | 清华大学 | Preparation method of hematopoietic tissue repairing material |
| CN101768345A (en) * | 2010-01-11 | 2010-07-07 | 山东省医疗器械研究所 | Polylactic acid degradable film |
-
2011
- 2011-12-22 CN CN 201110435502 patent/CN102532834B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1487025A (en) * | 2003-07-30 | 2004-04-07 | 复旦大学 | Thin-wall degradable tubular polymer material and its melting and injection molding process |
| CN1569253A (en) * | 2004-04-23 | 2005-01-26 | 清华大学 | Preparation method of hematopoietic tissue repairing material |
| CN101768345A (en) * | 2010-01-11 | 2010-07-07 | 山东省医疗器械研究所 | Polylactic acid degradable film |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111467581A (en) * | 2020-04-14 | 2020-07-31 | 广东赛珐生物科技有限公司 | Glaucoma drainage tube and preparation method thereof |
| CN111467581B (en) * | 2020-04-14 | 2022-04-12 | 广东赛珐生物科技有限公司 | Glaucoma drainage tube and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102532834B (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | Injectable in situ forming poly (l-glutamic acid) hydrogels for cartilage tissue engineering | |
| Li et al. | Poly (N-isopropylacrylamide)/poly (l-lactic acid-co-ɛ-caprolactone) fibers loaded with ciprofloxacin as wound dressing materials | |
| Siafaka et al. | Novel electrospun nanofibrous matrices prepared from poly (lactic acid)/poly (butylene adipate) blends for controlled release formulations of an anti-rheumatoid agent | |
| EP2476726B1 (en) | Processing of chitosan and chitosan derivatives | |
| Du et al. | Scaffold composed of porous vancomycin-loaded poly (lactide-co-glycolide) microspheres: A controlled-release drug delivery system with shape-memory effect | |
| DK2521534T3 (en) | FUNCTIONALIZED TRIBLE COPOLYMERS AND COMPOSITIONS CONTAINING SUCH POLYMERS | |
| WO2007124622A1 (en) | The 3d porous layered scaffold for tissue engineering and the preparation thereof | |
| Shang et al. | A conductive and biodegradable hydrogel for minimally delivering adipose-derived stem cells | |
| CN101422634A (en) | Ureteric branches support and preparation method thereof | |
| CN102532834B (en) | In-vivo degradable polymer tubular material for subcutaneous implantation of capsules and preparation method thereof | |
| Bhandari et al. | Electrically conducting smart biodegradable polymers and their applications | |
| US20180344652A1 (en) | Composition comprising polyelectrolyte complexes, methods and uses thereof | |
| US20230218379A1 (en) | An auxetic structure, a support structure, a method of preparing an auxetic structure, and use of a cellulosic material | |
| Ul‐Islam et al. | Structure, chemistry and pharmaceutical applications of biodegradable polymers | |
| Fang et al. | Acute toxicity evaluation of in situ gel-forming controlled drug delivery system based on biodegradable poly (ε-caprolactone)–poly (ethylene glycol)–poly (ε-caprolactone) copolymer | |
| CN100516110C (en) | Aliphatic polyester polymer, implantable medical device comprising the same and preparation method thereof | |
| CA2682291C (en) | Device made at least partially of n-acetylchitosan with controlled biodissolution | |
| KR20150116941A (en) | Hydrophilic nanofiber scaffold comprising PVP-b-PCL block copolymers | |
| Manandhar | Bioresorbable polymer blend scaffold for tissue engineering | |
| CN1232563C (en) | Poly acid anhydride for release-controlled medicine carrier and method for producing the same | |
| Pakdel et al. | A novel controlled release implant of insulin based on Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) polymer prepared by extrusion process | |
| Sverlinger et al. | Tuning physical and chemical attributes of the synthetic implant poly (L-lactic acid) and its effects on biological stimulation | |
| Abel | Poly (ester urea) s for Biomedical and Drug Delivery Applications | |
| Wei et al. | Polypropylene mesh coated with hyaluronic acid/polyvinyl alcohol composite hydrogel for preventing bowel adhesion | |
| Zhu et al. | 3D Printed Pelvic Organ Prolapse (POP) Tissue Scaffolds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGYIN BAOYIDE MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HARBIN ENGINEERING UNIV. Effective date: 20150112 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150001 HARBIN, HEILONGJIANG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150112 Address after: 214400, room 506, block A, Sha Shan Road, Jiangyin, Wuxi, Jiangsu, 85 Patentee after: JIANGYIN BAOYIDE MEDICAL TECHNOLOGY CO., LTD. Address before: 150001 Heilongjiang, Nangang District, Nantong street,, Harbin Engineering University, Department of Intellectual Property Office Patentee before: Harbin Engineering Univ. |